because of infection (48%, n ϭ 22 of 46). Cardiac events were the second most common cause of death (37%, n ϭ 17 of 46), followed by hemorrhage (11%, n ϭ 5 of 46; includes diverticulitis rupture, liver rupture, gastrointestinal bleeding, and pulmonary alveolar hemorrhage), and pulmonary complications (7%, n ϭ 3 of 46). One death was attributed to complications of metastatic lung cancer and 1 suffered from ischemic colitis because of superior mesenteric artery ischemia.
Overall, cardiac events were the most common cause of TRM (39%), closely followed by infectious complications (36%) and hemorrhage (12%). TRM was 12% (61 of 522) over the past 17 years, with TRM of 17% (52 of 310) during the first decade, and 4% (9 of 212) thereafter. The difference in mortality between these 2 time periods is statistically significant by 2 analysis, with a P value of .000012.
Successful treatment of AL amyloidosis remains a challenge because of organ dysfunction leading to an increased toxicity with any therapy. Particularly with HDM/SCT, TRM can be high. We and other centers have observed a decrease in TRM in recent years. 6 These improvements are likely because of: (1) refined patient selection, particularly with respect to detection of cardiac disease using biomarkers, cardiac MRI, and functional assessment of cardiopulmonary reserve; (2) optimized transplantation techniques including elimination of cyclophosphamide as a mobilization agent and incorporation of risk-adjusted melphalan dosing; (3) careful monitoring and management during the peri-transplant period, particularly with respect to fluid status, nutritional support, The treatment options for AL amyloidosis are rapidly evolving with the introduction of novel antiplasma cell agents for these patients, and antifibril therapies on the horizon. For now, treatment choices remain highly individualized, dependent on a careful assessment of performance status and organ function. HDM/SCT, with appropriate inclusion and exclusion criteria, remains an option in selected patients that offers a high rate of hematologic and organ responses and excellent overall survival. Ongoing examination of factors that impact mortality risk will continue to improve the risk-benefit ratio for this modality.
